



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known	
			Application Number	10/087,227
			Filing Date	February 27, 2002
			First Named Inventor	Alan F. Schatzberg et al.
			Group Art Unit	1646
Sheet 1 of 2	Examiner Name	Unassigned		
			Attorney Docket Number	STAN-261

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴ Kind Code ⁵ (if known)				
4/17			WO 01/37840A1	Schatzberg et al.	05/31/01		
			WO 99/59596	Schatzberg et al.	11/25/99		
			WO 99/17779	Schatzberg et al.	04/15/99		
9/13			WO 95/17192	Cohn et al.	06/29/1995		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
HWA		HEDLEY-WHITE et al., "Effect of Dexamethasone on Blood-Brain Barrier in the Normal Mouse" <i>Ann. Neurol.</i> (1986) 19:373-377		
		NEUWELT et al., "The Effect of Steroids on gentamicin delivery to brain after blood-brain barrier disruption" <i>J. Neurosurg.</i> (1990) 72:123-126		
		PAUL et al., "Inhibition of Blood-Barrier Disruption in Experimental Allergic Encephalomyelitis by Short-term Therapy with Dexamethasone or Cyclosporin A" <i>Int. J. Immunopharm.</i> (1995) 17:497-503		
		ZIYLAN et al., "Effect of Dexamethasone on Transport of α -Aminoisobutyric Acid and Sucrose Across the Blood-Brain Barrier" <i>J. Neurochem</i> (1988) 51:1338-1342		
		ZIYLAN et al., "Regional Alterations in Blood-to-Brain Transfer of α -Aminoisobutyric Acid and Sucrose, after Chronic Administration and Withdrawal of Dexamethasone" <i>J. Neurochem</i> (1989) 52:684-689		
		ZIYLAN et al., "Changes in the Permeability of the Blood-Brain Barrier in Acute Hyperammonemia" <i>Mol. And Chem Neuropath</i> (1993) 20:203-218		
Hm		Bornheim et al. "Effect of Cytochrome P450 Inducers on Cocaine-Mediated Hepatotoxicity" <i>Toxicology Tox. And Appl. Pharm.</i> (1988) 150:158-165		

4/21/04
Copied from 10008/22 on 09-02-2004



HH	LONG et al. "Blood-Brain Barrier: Endogenous Modulation by Adrenal-Cortical Function" <i>Science</i> (1985) 227:1580-1583	
HH	IWEN et al. "Enhancement of Ketoconazole Penetration across the Blood-brain Barrier of Mice by Dimethyl Sulfoxide" <i>Antimicrobial Agents and Chemotherapy</i> , Oct. 1986, p. 614-618	
HH	PERFECT et al. "Comparison of Itraconazole and Fluconazole in Treatment of Cryptococcal Meningitis and Candida Pyelonephritis in Rabbits" <i>Antimicrobial Agents and Chemotherapy</i> , APR. 1986, p. 579-583	
HH	GAILLARD et al. "Corticosteroid Regulation of Blood-Brain Barrier Permeability" <i>Society for Neuroscience</i> , Vol. 23, 1997 pp 229 Abstract XP-001057484	
Examiner Signature	James H. Hume	Date Considered 7/7/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.
Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Wayne Jones

4/4/03